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Abstract objectives Recent studies in Central America indicate that mortality attributable to chronic kidney
disease (CKD) is rising rapidly. We sought to determine the prevalence and regional variation of
CKD and the relationship of biologic and socio-economic factors to CKD risk in the older-adult
population of Costa Rica.
methods We used data from the Costa Rican Longevity and Health Aging Study (CRELES). The
cohort was comprised of 2657 adults born before 1946 in Costa Rica, chosen through a sampling
algorithm to represent the national population of Costa Ricans >60 years of age. Participants
answered questionnaire data and completed laboratory testing. The primary outcome of this study
was CKD, defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2.
results The estimated prevalence of CKD for older Costa Ricans was 20% (95% CI 18.5–21.9%).
In multivariable logistic regression, older age (adjusted odds ratio [aOR] 1.08 per year, 95% CI
1.07–1.10, P < 0.001) was independently associated with CKD. For every 200 m above sea level of
residence, subjects’ odds of CKD increased 26% (aOR 1.26 95% CI 1.15–1.38, P < 0.001). There
was large regional variation in adjusted CKD prevalence, highest in Limon (40%, 95% CI 30–50%)
and Guanacaste (36%, 95% CI 26–46%) provinces. Regional and altitude effects remained robust
after adjustment for socio-economic status.
conclusions We observed large regional and altitude-related variations in CKD prevalence in
Costa Rica, not explained by the distribution of traditional CKD risk factors. More studies are
needed to explore the potential association of geographic and environmental exposures with the risk
of CKD.
keywords Chronic kidney disease, Costa Rica, Epidemiology, Mesoamerican nephropathy, Tropical
chronic disease, Altitude
Introduction
Many developing countries have experienced a surge in
chronic disease states, including chronic kidney disease
(CKD) [1–3]. CKD is a major risk factor for cardiovas-
cular morbidity and mortality, and among the world’s
growing elderly population, CKD is also an indepen-
dent risk factor for physical and cognitive dysfunction
and poor quality of life [4, 5]. As adverse outcomes
can often be prevented by early identification of CKD,
improving knowledge of population-specific distribu-
tions and determinants of CKD is a public health pri-
ority [6, 7]. At present, the burden and determinants
of CKD have been thoroughly characterised only in
high-income countries [8]. For example, in the United
States (USA), there is an estimated national prevalence
of CKD of 11.6% [9], although higher prevalence is
observed in socio-economically disadvantaged subgroups
[10, 11]. Older age is the strongest predictor of CKD
in the USA [12, 13]; where, the prevalence of CKD in
individuals over the age of 60 years is 20%, and 35%
among those over 70 years [9]. However, little is
known about the epidemiology of CKD in low- and
middle-income countries, where populations are also
ageing but there are fewer resources to handle the
sequelae of CKD including high healthcare costs, dis-
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ability, morbidity and mortality. Additionally, there are
likely determinants of CKD that are distinct to devel-
oping countries. For example, in sub-Saharan Africa,
high rates of communicable disease (e.g. human
immunodeficiency virus) [14] and unique population
genetics have been postulated to confer vulnerability to
developing CKD [15].
In Central America, the rates of renal replacement ther-
apy and transplantation for CKD have steadily increased
in recent years, and some countries have reported alarm-
ing increases in mortality rates attributed to CKD [16,
17]. Costa Rica is a middle-income country in Central
America that is known for its population’s longevity,
social development, universally available healthcare and
decline in mortality from communicable disease [18].
However, a study of Costa Rican vital statistics revealed
that age-standardised mortality rates from CKD doubled
among men and quadrupled among women from 1970 to
2012 [19].
The Costa Rican population is comprised of 4.3 mil-
lion inhabitants, 7% aged 65 years and older, with 24%
residing in the three lowland and primarily agricultural
provinces of Guanacaste and Puntarenas on the Pacific
coast and Limon on the Caribbean coast (Figure 1). The
remaining population resides in four more urbanised cen-
tral provinces, namely San Jose, Alajuela, Cartago and
Heredia, with the majority of the population living in the
highlands of the Central Valley, including the metropoli-
tan area of San Jose [20].
Previous work has highlighted the increasing preva-
lence of traditional CKD risk factors in Costa Rica,
including an ageing population [21], and increased preva-
lence of hypertension [22] and diabetes [23]. In addition,
a recently characterized nephropathy called CKDnT
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Figure 1 Map of Costa Rica with regional CKD prevalence, annual heat exposure and altitude
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(CKD of non-traditional causes) [24, 25] has been discov-
ered at epidemic levels among young Costa Ricans and
other Central Americans without traditional CKD risk
factors, and may partially explain the rising mortality
from CKD in the region. Hypotheses for the causative
factor of CKDnT include toxic exposures (e.g. traditional
medicines, pesticides) [26], geographic factors (e.g. heat
and altitude effects) and harsh working conditions of
agricultural workers [14, 27–30].
As the population worldwide is ageing, there is a need
to identify potential risk factors for CKD in older popula-
tions in developing countries such as Costa Rica, includ-
ing geographic, socio-economic and educational
differences among citizens that drive health behaviours
[31] and disparate access to medical care [32]. Therefore,
using nationally representative data from the Costa Rican
Study of Longevity and Healthy Aging (CRELES), our
objectives were to determine: (i) the prevalence levels of
CKD in the older-adult population of Costa Rica, (ii) the
relationship of biologic and socio-economic factors to
CKD risk and (iii) the regional variation in CKD preva-
lence in Costa Rica.
Methods
Data source and study participants
Our data source was the publicly available CRELES data-
base [33]. CRELES is a longitudinal study of a nationally
representative sample of 2827 Costa Rican adults born in
or prior to 1946. We used data from the first two waves
of surveys, which took place mostly in 2005 and 2007.
The first survey wave of CRELES collected data on 2827
individuals. The sampling strategy for the study, which
included oversampling of older ages, has been described
elsewhere [34]. Approximately 5% of participants
declined to provide the blood sample in each wave. The
final sample in the first survey wave comprised 2657 indi-
viduals (94%) who had laboratory data collected on
renal function.
Participants completed in-depth interviews on self-
reported health status, functional status, healthcare utili-
sation and life-course socio-economic conditions. All data
and specimens in the study were collected at the partici-
pants’ homes, usually during two visits, using hand-held
computers. During the first visit, participants answered a
90-minute questionnaire (including some mobility tests
and two blood pressure measures) and a 10-minute food
frequency questionnaire. The interviewer also checked
and recorded all medication prescribed by a healthcare
professional. During a second visit early the next day,
fasting blood samples were collected by venipuncture: 1
EDTA purple top tube (for 3–4 ml of whole blood) and
2 serum-separating tubes with a clot activator (for 10–
12 ml of blood, to obtain 4–6 ml of serum). Specimens
were analysed in several laboratories (three laboratories
for serum creatinine) according to the methods described
elsewhere, which include linear adjustments to have com-
parable measurements across laboratories [35]. Serum
creatinine measurements were calibrated using the Roche
method for isotope dilution-mass spectrometry [36]. The
institutional review board of the University of Costa Rica
granted human subjects approval to CRELES, and all
participants granted their informed consent by means of
their signature.
Definition of CKD
We calculated estimated glomerular filtration rate (eGFR)
based on the 2009 CKD-EPI equation [37, 38]. The
CKD-EPI equation utilises data on participant age, sex
and race, although race was not relevant in the current
analysis. We then categorised eGFR categories per the
2012 Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines, as follows: G1) eGFR≥90 ml/min/
1.73 m2, G2) eGFR ≥60 and <90 ml/min/1.73 m2, G3a)
eGFR ≥45 and <60 ml/min/1.73 m2, G3b) eGFR ≥30 and
<45 ml/min/1.73 m2, G4) eGFR< 30 and ≥15 ml/min/
1.73 m2, G5) <15 ml/min/1.73 m2. As urine albumin
data were not available to identify CKD at higher eGFR
levels, only participants with eGFRs in categories G3a,
G3b, G4 and G5 were categorised as having CKD [39].
Hypothesised risk factors
We explored the following putative risk factors for CKD
that are unique to Central America and Costa Rican
older adults: province of residence [19] and altitude of
residence above sea level [30]. We also explored the asso-
ciation of socio-economic status (SES, based on a coun-
try-specific wealth scale) and educational attainment on
the risk of CKD. The residential altitude of the CRELES
respondents was an ecological variable representing the
mean altitude of their district of residence, which is the
smallest geographic unit in Costa Rica (i.e. there are 473
districts among the seven Costa Rican provinces).
Known CKD risk factors
We examined the strength of the association between
known CKD risk factors to CKD prevalence in Costa
Rica by considering the subjects’ medical history of
hypertension and diabetes. We also adjusted for metrics
of poor metabolic control that may lead to CKD includ-
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ing elevated glycosylated haemoglobin (HbA1C, ≥6.5%)
[40], poorly controlled blood pressure (SBP ≥150 mmHg
or DBP ≥90 mmHg) [41] and obesity (defined as having
a body mass index (BMI) higher than 30 kg/m2). We
adjusted for reported medication use for diabetes, hyper-
tension or hyperlipidaemia. The following variables were
also considered potential confounders in this analysis:
sex, age, income, years of education, recent physician vis-
its and smoking history.
Statistical analysis
To identify the association of our hypothesised risk fac-
tors with CKD among elderly Costa Ricans, we first
explored their univariate associations with CKD. Then,
we estimated the prevalence of CKD by sex, age, alti-
tude and province. Finally, we fit multivariable logistic
regression models for CKD using covariates that were
significant (P-value threshold <0.2) at the univariate
level. To identify regions with risk of CKD above that
expected by traditional risk factors, we estimated CKD
prevalence per region after adjustment for covariates
identified in our multivariable model. Statistical analyses
were conducted using STATA MP version 13.0 (Stata
Corporation, 2013). Descriptive statistics included pro-
portions for categorical variables, and means for contin-
uous variables, with 95% confidence intervals (CI). All
statistical analyses took into account differential sam-
pling weights.
Sensitivity analysis
As the CKD definition based on KDIGO guidelines
includes evidence of consistently low eGFR in repeat test-
ing after 90 days [39], we performed a sensitivity analysis
utilising repeat measures of eGFR from the second wave
of CRELES, conducted close to two years later.
Results
Bivariate analysis
The first survey wave of CRELES collected data on
2827 individuals, of whom 2657 (94%) had laboratory
data collected on renal function. Of these individuals,
744 survey participants had evidence of CKD by eGFR
criteria (eGFR<60 ml/min/1.73 m2) [39]. The average
age of the study sample was 76 years (standard error
1.3 years); 45% were male and 20% were diabetic.
Subjects with CKD were more likely to be older,
female, diabetic and hypertensive (Table 1). Subjects
with CKD also had lower educational attainment,
higher systolic blood pressure, and were more likely to
be taking medications for diabetes, hypertension and
hyperlipidaemia. A greater proportion of subjects with
CKD had recently seen a physician and lived at higher
altitude. There were also differences in the proportion
of subjects with CKD between provinces. There were
no significant (at the P < 0.05 level) bivariate
associations between CKD and income or wealth sta-
tus.
National CKD prevalence
The estimated prevalence of CKD for older Costa
Ricans was 20% (95% CI: 19–22%); 23% (95% CI:
21–26%) among females; and 17% (95% CI: 14–19%)
among males. CKD prevalence increased in a nearly lin-
ear fashion with age, from about 15% at age 60 years
to greater than 50% at age 90 years (Figure 2). When
further categorised by stage of CKD [39], prevalence of
stage 3a was 14% (95% CI: 12–16%) among males
and 20% (95% CI: 17–22%) among females, whereas
stages 3b-5 CKD were present in 6% (95% CI: 4–7%)
of males and 6% (95% CI: 5–7%) of females. Women
exhibited a higher CKD prevalence than men at all ages,
although among individuals over the age of 80 years,
the difference between sexes was no longer statistically
significant.
Aetiologic model of CKD
The results of our multivariable modelling approach for
CKD among elderly Costa Ricans are reported in
Table 2. In the first model, we examined the associa-
tion of province and altitude of residence, adjusted for
age and gender, on the risk of CKD. In this model,
subjects of older age (aOR 1.08 per year, 95% CI:
1.07–1.10, P < 0.001) and female subjects (aOR 1.44,
95% CI: 1.13–1.83, P = 0.003) were more likely to
have CKD. Adjusted for age and gender, living at
higher altitudes was independently associated with
higher risk of CKD (aOR 1.28 for every 200-m
increase above sea level, 95% CI: 1.13–1.83,
P < 0.001). Also, compared to the capital province of
San Jose, residence in Guanacaste (aOR 3.43, 95% CI:
1.84–6.38, P < 0.001), Puntarenas (aOR 1.99, 95% CI:
1.14–3.48, P = 0.02) or Limon (aOR 4.84, 95% CI:
2.56–9.15, P < 0.001) was independently associated
with higher risk of CKD. Adding SES and comorbidity
risk factors to the multivariable model did not substan-
tively change our findings of altitude and regional
effects, but did attenuate the effect of female gender on
CKD risk. In the fully adjusted model, other risk fac-
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tors for CKD included having poorly controlled blood
pressure (aOR 1.60, 95% CI: 1.10–2.32, P = 0.01),
taking diabetes medication (aOR 1.73, 95% CI: 1.04–
2.87, P = 0.04), hypertension medication (aOR 1.52,
95% CI: 1.06–2.18, P = 0.02), and lipid-lowering medi-
cation (aOR 1.48, 95% CI: 1.10–1.99, P = 0.01). The
adjusted CKD prevalence increased monotonically from
10.4% (95% CI: 6.8–13.9%) for regions below 200 m
to 26.5% (95% CI: 18.2–34.1%) for regions at 1400–
1799 m above sea level (Figure 3). There were not
enough observations of subjects living at altitudes
higher than 1800 metres (n = 23) to produce stable
estimates in this model.
Regional variation in CKD prevalence
Estimates of CKD prevalence by province differed sub-
stantially depending on whether altitude effects were
included (Table 3, Figure 1). Adjusting for age and gen-
der, the lowest CKD prevalence rates were observed in
Alajuela and Puntarenas (14% and 15%, respectively),
while the highest prevalence rates were observed in Car-
tago and Limon (28% and 25%, respectively). However,
after further adjusting for the effect of altitude, San Jose,
Alajuela and Heredia had the lowest CKD prevalence
(16% for all), and Guanacaste and Limon had the highest
(37% and 42%, respectively).
Table 1 Characteristics of elderly Costa Ricans by CKD status in Wave 1
No CKD n = 1913 CKD (stage 3a-5) n = 744 P-value
Mean age, years 69.2 [68.8–69.6] 74.6 [73.7–75.4] <0.001
Per cent male (n = 1211) 49.6 [46.9,52.3] 39.4 [34.9,44.1] <0.001
Per cent with reported diabetes (n = 517) 20.1 [18.1,22.4] 25.4 [21.5,29.9] 0.02
Per cent with reported hypertension (n = 1307) 45.1 [42.4,47.8] 63.1 [58.5,67.5] <0.0001
Mean years of education 5.3 [5.0–5.5] 4.9 [4.5–5.3] 0.17
Education category, %
Less than primary school (n = 1862) 50.1 [47.4,52.8] 56.9 [52.0,61.7] 0.02
Primary school and beyond (n = 795) 49.9 [47.2,52.6] 43.1 [38.3,48.0]
Mean income (monthly thousands of Colones) 307 [247–367] 261 [203–320] 0.34
Per cent visited physician in last
12 months (n = 2380)
86.8 [84.7,88.6] 95.2 [92.7,96.9] <0.0001
Mean wealth proxy/scale of goods 8.2 [8.1–8.3] 8.2 [8.1–8.4] 0.66
Mean altitude of home above sea level, m 795 [767–824] 931 [882–979] <0.001
Per cent rural residence (n = 981) 35.3 [32.8,37.9] 32 [27.9,36.3] 0.20
Province of residence, %
San Jose (n = 928) 35.7 [33.1,38.3] 36.3 [31.9,40.9] <0.001
Alajuela (n = 425) 16.6 [14.7,18.7] 10.3 [8.1,13.1]
Cartago (n = 413) 13.9 [12.2,15.9] 23 [19.2,27.4]
Heredia (n = 188) 8.3 [6.8,10.0] 7.7 [5.3,11.1]
Guanacaste (n = 275) 9.5 [8.0,11.2] 8.8 [6.6,11.7]
Puntarenas (n = 254) 9.8 [8.3,11.5] 6.3 [4.7,8.5]
Limon (n = 174) 6.3 [5.1,7.8] 7.5 [5.6,10.1]
Per cent current smoker (n = 211) 11.2 [9.5,13.2] 5.1 [3.3,7.7] <0.001
Mean HbA1C, % 5.7 [5.7–5.8] 5.9 [5.8–6.0] 0.008
Per cent with HbA1C ≥ 6.5% (n = 350) 13.3 [11.6,15.3] 17 [13.6,21.0] 0.07
Mean systolic blood pressure, mmHg 143.4 [142.2–144.6] 147.0 [144.7–149.3] 0.006
Mean diastolic blood pressure, mmHg 83.9 [83.3–84.5] 83.5 [82.2–84.8] 0.49
Per cent with measured hypertension
(>150/90) (n = 1212)
42.2 [39.5,44.9] 50.5 [45.8,55.1] 0.002
Per cent BMI > 30 kg/m2 (n = 593) 27.4 [24.9,29.9] 26.4 [22.3,30.9] 0.70
Per cent taking medication for
Diabetes (n = 424) 16.3 [14.4,18.4] 23.3 [19.4,27.7] 0.002
Hypertension (n = 1210) 39.5 [36.9,42.2] 61.2 [56.5,65.6] <0.0001
Hyperlipidaemia (n = 498) 18.8 [16.8,21.0] 30.7 [26.3,35.4] <0.001
CKD defined as eGFR<60 ml/min/1.73 m2.
Continuous variables are reported as means, and categorical variables as percentages, with 95% confidence intervals in brackets.
The reported sample sizes (n) for categorical variables are the number of survey participants within each category. CKD, chronic kid-
ney disease.
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Sensitivity analysis
Appendix 1 reports the results of a sensitivity analysis
incorporating available longitudinal data on subjects, col-
lected from the second survey wave of CRELES (conducted
two years after the first wave). Seventy-seven per cent of
subjects had repeat eGFRmeasures in the second survey
wave; the resulting analytical sample for the sensitivity
analysis contained 4740 observations. We found that the
strength of the associations observed between age, region,
altitude and CKD risk remained consistent and statistically
significant, although the observed elevated risk of CKD in
Limon and Guanacaste provinces was lower (aOR of 2.72
vs. 4.53 and 2.66 vs. 3.65, respectively). The use of the two
waves of survey data resulted in slightly higher estimates of
national CKD prevalence: 26% (95%CI: 24–28%) among
all older adults, 23% (95%CI: 20–25%) among older
males and 29% (95%CI: 27–34%) among older females.
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Figure 2 Prevalence of CKD by age and sex (smoothed with
locally weighted polynomials)
Table 2 Aetiologic model of CKD in Costa Rica: regional and traditional risk factors
Model 1 Model 1 + SES & comorbidities
aOR 95% CI P-value aOR 95% CI P-value
Age (per 1-year increase) 1.08 [1.07,1.10] <0.001 1.08 [1.07,1.10] <0.001
Female 1.44 [1.13,1.83] 0.003 1.20 [0.93,1.56] 0.16
Altitude (per 200-m increase from sea level) 1.28 [1.17,1.40] <0.001 1.26 [1.15,1.38] <0.001
Province of Residence*
Alajuela 1.01 [0.69,1.49] 0.95 1.02 [0.69,1.51] 0.93
Cartago 1.37 [0.97,1.94] 0.07 1.37 [0.96,1.95] 0.09
Heredia 0.93 [0.55,1.58] 0.79 0.84 [0.51,1.41] 0.51
Guanacaste 3.43 [1.84,6.38] <0.001 3.65 [1.91,6.97] <0.001
Puntarenas 1.99 [1.14,3.48] 0.02 2.14 [1.19,3.83] 0.01
Limon 4.84 [2.56,9.15] <0.001 4.53 [2.35,8.76] <0.001
Education (per 1-year increase) 1.00 [0.97,1.03] 0.84
Recent MD Visit 1.64 [0.94,2.87] 0.08
Current smoker 0.65 [0.36,1.16] 0.15
Diagnosed with DM 0.63 [0.39,1.03] 0.07
Diagnosed with HTN 1.25 [0.87,1.80] 0.22
HbA1C % (per 1-% increase) 1.11 [0.95,1.29] 0.18
HbA1C% > 6.5 0.89 [0.47,1.71] 0.74
Systolic blood pressure (per 1-mmHg increase) 0.99 [0.99,1.00] 0.08
BP >150/90 1.60 [1.10,2.32] 0.01
BMI> 30 kg/m2 0.93 [0.69,1.25] 0.64
Prescribed medication for:
DM 1.73 [1.04,2.87] 0.04
HTN 1.52 [1.06,2.18] 0.02
Hyperlipidaemia 1.48 [1.10,1.99] 0.01
*Reference: San Jose.
aOR, adjusted odds ratio; CI, confidence interval; CKD, chronic kidney disease; SES, socio-economic status; m, metre; MD, medical
doctor; DM, diabetes mellitus; HTN, hypertension; HbA1C, glycosylated haemoglobin; mmHg, millimetre mercury; BP, blood pres-
sure; BMI, body mass index.
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Discussion
The prevalence of CKD is increasing worldwide, likely
driven by an ageing population [8]. Worldwide death
rates attributable to CKD have also risen dramatically,
with a median increase of 36.9% from 1990 to 2013
[42]. In addition to heightened mortality risk, older
adults with CKD are also more likely to suffer disability
from physical and cognitive dysfunction [5]. However,
determinants of CKD are poorly understood in the ageing
population of developing countries, including those in
Central America. In this study, we explored traditional
and novel risk factors for CKD in a nationally representa-
tive sample of elderly Costa Ricans. We have identified
that the prevalence of CKD among older Costa Ricans is
20%, similar to the CKD prevalence previously described
among older adults in the USA [9]. Our study also found
that the prevalence of CKD among older Costa Rican
women is higher than among older Costa Rican men.
Previous studies have highlighted that women in Costa
Rica have higher burdens of hypertension, diabetes and
obesity [43]. Consistent with these reports, our study
showed that after adjustment for comorbidities and SES,
the association of female gender and CKD was no longer
statistically significant. Also, while wealth and education
disparities are also known to drive differential risk for
chronic disease states including CKD
[10, 16, 31, 32, 44], our study did not find wealth or
education gradients with CKD among elderly Costa
Ricans. This may be explained by the fact that while
most of the subjects had low educational attainment, the
vast majority also had recent access to medical care.
Indeed, nephrologic clinical services have been freely
accessible in Costa Rica since 1968, as part of the
national social security system that ensures that citizens
have free access to medical attention as needed [45].
Therefore, the lack of socio-economic gradients in CKD
may represent a success in Costa Rica’s adoption of wide-
spread health care coverage [18].
Our study also highlighted a potential relationship
between altitude of residence and risk of CKD. The asso-
ciation between altitude and CKD risk remained robust
after adjustment for age, comorbidities, region, wealth,
education and access to recent medical care. Living at
high altitudes is a known risk factor for high-altitude
renal syndrome (HARS), a syndrome resulting from
chronic hypoxia that is characterised by polycythaemia,
hyperuricaemia, hypertension and proteinuria
[30, 46, 47]. However, this syndrome has generally been
described at altitudes higher than 2400 m above sea
level, and most Costa Ricans live either at sea level or in
the Central Valley, about 1200 m above sea level. It is
possible that the direct renal injury or reduction in renal
plasma flow observed in HARS is present to a lesser
degree at the highest altitudes in Costa Rica and that
older adults are particularly susceptible to these expo-
sures. However, further studies are needed to understand
possible factors related to higher altitude that may
explain the patterns observed in this study.
This study also identified Guanacaste and Limon pro-
vinces as the regions in Costa Rica with the highest
prevalence rates of CKD. A recent study of Costa Rican
death records over the last 40 years noted that Gua-
nacaste province had the most marked rise in age-
adjusted CKD mortality [19]. These findings in aggregate
warrant future studies to further investigate risk factors
specific to these regions, including factors that may dis-
tinguish Guanacaste and Limon from Puntarenas, the
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Figure 3 Prevalence of CKD by altitude of residence, adjusted
for age, gender, comorbidities and province of residence
Table 3 Adjusted CKD prevalence by province
Province
Age and gender
adjusted
Age, gender and
altitude adjusted
Prevalence
(%) 95% CI
Prevalence
(%) 95% CI
San Jose 20 (17–22) 16 (14–19)
Alajuela 14 (11–17) 16 (12–19)
Cartago 28 (23–33) 23 (18–28)
Heredia 20 (13–28) 16 (10–22)
Guanacaste 19 (14–25) 37 (25–48)
Puntarenas 15 (11–19) 25 (17–33)
Limon 25 (18–31) 42 (31–54)
CI, confidence interval; CKD, chronic kidney disease.
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other low-altitude coastal province in Costa Rica. In
terms of putative differences in environmental exposures,
residents of the low-altitude provinces typically encounter
warmer weather than the central provinces (Figure 1)
and rely more on agriculture for commerce than residents
of the Central Valley. The agricultural products of these
regions are distinct: according to the 2014 agricultural
census, the main crops in Guanacaste are beef, sugar cane
and rice, whereas in Limon, bananas and other fruits are
the predominant export items [48]. Guanacaste and
Limon have also attracted the highest proportions of
immigrants from other Central American countries,
including Nicaragua, where the epidemic of CKDnT has
been extensively documented [29, 49, 50]. While the
causes of CKDnT are unknown [50], hypotheses include
heat stress caused by year-round extreme high tempera-
tures and humidity, heavy agricultural work and toxic
pesticides. These factors are thought to predispose certain
individuals to recurrent volume depletion, resulting in
activation of both intrarenal and extrarenal pathways
that drive renal injury [51]. However, while CKDnT have
been characterised as a tubulointerstitial nephropathy
with low-grade proteinuria [24, 52], previous reports of
kidney biopsies performed among Costa Ricans with
CKD have identified focal and segmental glomeruloscle-
rosis, membranous nephropathy, mesangial proliferative
glomerulonephritis and crescent glomerulonephritis as the
most common findings [45]. Future studies, ideally
including data on environmental exposures and kidney
biopsies, will be important to elucidate the nature of
CKD found among populations living in different regions
of Costa Rica.
Study limitations
Our study has several limitations that must be acknowl-
edged. As some of our data are cross-sectional, we cannot
make inferences on causality. Also, while we attempted
to remain as consistent as possible to the 2012 Clinical
Practice Guidelines from the KDIGO working group rec-
ommendations on the diagnosis of CKD [39], we did not
have data on proteinuria that is necessary to characterise
early CKD (e.g. stage 2, eGFR between 60 and 90 ml/
min). Therefore, we chose to categorise subjects as having
CKD only at later stages (i.e. 3a and beyond), as protein-
uria is not a necessary component for diagnosis at later
stages of renal dysfunction, and the CKD-EPI formula is
more precise [39]. In addition, there is an active debate
on whether stage 3a CKD represents a pathologic condi-
tion or a consequence of natural ageing among the
elderly [53]. However, in one global study of over two
million participants, Hallan and colleagues found that
while older age attenuated the risk of mortality with
declining eGFR, the relative risk of mortality was signifi-
cantly higher, even among the oldest participants
(age>75 years), when eGFR was 56 ml/min/1.73 m2 or
lower [54]. The health consequences of CKD for older
adults include higher risk of morbidity and mortality,
even at higher levels of eGFR [5, 12]. Therefore, we
chose to include mild reductions in eGFR (corresponding
to CKD stage 3a) in our estimates. CRELES investigators
did not perform serial measurements of eGFR during the
first wave of surveys. Therefore, as the classification of
CKD requires two eGFR measurements at least 90 days
apart [39], we completed a sensitivity analysis including
data from the second survey wave, completed two years
after the initial wave. The resulting longitudinal random-
effects models confirmed the significant associations we
observed between province, altitude and CKD in Costa
Rica.
Conclusion
In Central America, where data are scarce on the epidemi-
ology of CKD, studies are urgently needed to explain the
rising prevalence of CKD and precipitous rise in CKD-
related deaths. While we did not identify socio-economic
disparities in CKD risk among elderly Costa Ricans, our
findings of potential geographic and regional determinants
of CKD in Costa Rica provide a platform for further
investigation.
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Appendix1
Longitudinal aetiologic model of CKD in Costa Rica.
Model 1 Model 1 + SES & comorbidities
aOR 95% CI P-value aOR 95% CI P-value
Age 1.13 [1.11,1.15] <0.001 1.13 [1.11,1.15] <0.001
Female 1.55 [1.23,1.97] <0.001 1.23 [0.97,1.57] 0.09
Altitude (per 200 m) above sea level 1.25 [1.14,1.36] <0.001 1.23 [1.13,1.34] <0.001
Province of Residence*
Alajuela 0.92 [0.61,1.37] 0.67 0.95 [0.64,1.43] 0.82
Cartago 1.22 [0.86,1.72] 0.27 1.29 [0.91,1.83] 0.15
Heredia 1.49 [0.97,2.30] 0.07 1.31 [0.85,2.01] 0.22
Guanacaste 2.33 [1.27,4.28] 0.01 2.66 [1.45,4.89] 0.00
Puntarenas 1.22 [0.68,2.19] 0.50 1.38 [0.77,2.48] 0.28
Limon 2.95 [1.53,5.68] <0.001 2.72 [1.41,5.25] <0.001
Years of education 1.02 [0.99,1.05] 0.24
No insurance 0.91 [0.67,1.24] 0.57
Recent MD visit 1.07 [0.72,1.61] 0.73
Current smoker 0.6 [0.38,0.95] 0.03
Diagnosed with DM 0.71 [0.44,1.16] 0.18
Diagnosed with HTN 1.8 [1.31,2.48] <0.001
HbA1C % 1.1 [0.96,1.26] 0.17
HbA1C % > 6.5 1.88 [1.24,2.86] 0.00
Systolic BP (per mmHg rise) 0.99 [0.98,1.00] 0.01
BP > 150/90 1.3 [0.96,1.76] 0.09
BMI > 30 kg/m2 0.97 [0.75,1.25] 0.81
Prescribed medication for:
DM 1.29 [0.78,2.14] 0.32
HTN 1.6 [1.18,2.16] <0.001
Hyperlipidaemia 1.53 [1.20,1.96] <0.001
N = 2681 individuals and 4740 observations.
*Reference: San Jose.
aOR, adjusted odds ratio; CI, confidence interval; m, metre; SES, socio-economic status; MD, medical doctor; DM, dia-
betes mellitus; HTN, hypertension; HbA1C, glycosylated haemoglobin; mmHg, millimetre mercury; BP, blood pressure;
BMI, body mass index.
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